Clinical Trials Browser

Phase 2/3 × pembrolizumab × Thoracic × Clear all

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06712316 2026-03-17

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-03-17

MountainTAP-29

Phase 2/3 Recruiting

Lung Neoplasms

NCT04093167 2026-03-11

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Phase 2/3 Recruiting

Lung Neoplasms

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

Squamous NSCLC

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2/3 Completed

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT04322617 2024-06-04

ATHENA

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01905657 2021-10-06

MK-3475-010

Phase 2/3 Completed

1,034 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer